National consensus regarding azithromycin use in cystic fibrosis;Consensus national sur la prescription de l'azithromycine dans la mucoviscidose

Revue des Maladies Respiratoires

Volumn 32, Issue 6, 2015, Pages 557-565

  Abely, M ^a   Jubin, V ^b   Bessaci Kabouya, K ^a   Chiron, R ^c   Bui, S ^d   Fayon, M ^d  

^a AMERICAN MEMORIAL HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c HÔPITAL ARNAUD DE VILLENEUVE   (France)

^d HÔPITAL PELLEGRIN   (France)

Author keywords

Azithromycin; Consensus; Cystic fibrosis; Delphi; Inflammation

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CYSTIC FIBROSIS; DELPHI STUDY; DRUG TOLERANCE; FOLLOW UP; HUMAN; PRESCRIPTION; TREATMENT DURATION; ADOLESCENT; ADULT; CHILD; CONSENSUS; FRANCE; MICROBIOLOGY; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CONSENSUS; CYSTIC FIBROSIS; FRANCE; HUMANS; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 84938340874     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2014.10.733     Document Type: Article

References (53)

1. Fayon M, Chiron R, Abely M. Mesure de l'inflammation pulmonaire dans la mucoviscidose. Rev Mal Respir 2008;25:705-24.
2. Hutchison ML, Govan JR. Pathogenicity of microbes associated with cystic fibrosis. Microbes Infect 1999;1:1005-14.
3. Hoiby N, Krogh Johansen H, Moser C, et al. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001;3:23-35.
4. Bonnett CR, Cornish EJ, Harmsen AG, et al. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus Conidia. Infect Immun 2006;74:6528-39.
5. Mircescu MM, Lipuma L, van Rooijen N, et al. Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J Infect Dis 2009;200:647-56.
6. Park SJ, Mehrad B. Innate immunity to Aspergillus species. Clin Microbiol Rev 2009;22:535-51.
7. Schaffner A, Davis CE, Schaffner T, et al. In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest 1986;78:511-24.
8. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004;117:5S-11S.
9. Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother 2007;51:3677-87.
10. Nguyen D, Emond MJ, Mayer-Hamblett N, et al. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 2007;42:533-41.
11. Tateda K, Ishii Y, Matsumoto T, et al. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother 2000;6:1-7.
12. Wagner T, Soong G, Sokol S, et al. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 2005;128:912-9.
13. Slater M, Rivett DW, Williams L, et al. The impact of azithromycin therapy on the airway microbiota in asthma. Thorax 2014;69:673-4.
14. Halldorsson S, Gudjonsson T, Gottfredsson M, et al. Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 2010;42:62-8.
15. Shimizu T, Shimizu S. Azithromycin inhibits mucus hypersecretion from airway epithelial cells. Mediators Inflamm 2012;2012:265714.
16. Guillot M, Amiour M, El Hachem C, et al. Macrolides, Pseudomonas aeruginosa et mucoviscidose : concepts actuels. Arch Pediatr 2006;13:S48-50.
17. Clement A, Tamalet A, Leroux E, et al. Long-term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006;61:895-902.
18. Corvol H, Taytard J, Thouvenin G, et al. Pourquoi utiliser les macrolides au long cours en pneumologie pédiatrique ? Arch Pediatr 2014;21:314-21.
19. Equi A, Balfour-Lynn IM, Bush A, et al. Long-term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84.
20. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420.
21. Kabra SK, Pawaiya R, Lodha R, et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. J Cyst Fibros 2010;9:17-23.
22. McCormack J, Bell S, Senini S, et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 2007;30:487-95.
23. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
24. Steinkamp G, Schmitt-Grohe S, Doring G, et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008;102:1643-53.
25. Wolter J, Seeney S, Bell S, et al. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-6.
26. Southern KW, Barker PM, Solis-Moya A, et al. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2011:CD002203.
27. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010;303:1707-15.
28. Mayell SJ, Munck A, Craig JV, et al. European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009;8:71-8.
29. Kobayashi H, Ohgaki N, Takeda H. Therapeutic possibilities for diffuse panbronchiolitis. Int J Antimicrob Agents 1993;3:S81-6.
30. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand [B] 1974;82:551-8.
31. Saint-Criq V, Ruffin M, Rebeyrol C, et al. Azithromycin fails to reduce inflammation in cystic fibrosis airway epithelial cells. Eur J Pharmacol 2012;674:1-6.
32. Yamasawa H, Oshikawa K, Ohno S, et al. Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. Am J Respir Cell Mol Biol 2004;30:569-75.
33. Phaff SJ, Tiddens HA, Verbrugh HA, et al. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 2006;57:741-6.
34. Cascaval RI, Lancaster DJ. Hypersensitivity syndrome associated with azithromycin. Am J Med 2001;110:330-1.
35. Chandrupatla S, Demetris AJ, Rabinovitz M. Azithromycininduced intrahepatic cholestasis. Dig Dis Sci 2002;47:2186-8.
36. Kamada AK, Hill MR, Ikle DN, et al. Efficacy and safety of lowdose troleandomycin therapy in children with severe, steroidrequiring asthma. J Allergy Clin Immunol 1993;91:873-82.
37. Lockwood AM, Cole S, Rabinovich M. Azithromycin-induced liver injury. Am J Health Syst Pharm 2010;67:810-4.
38. Longo G, Valenti C, Gandini G, et al. Azithromycin-induced intrahepatic cholestasis. Am J Med 1997;102:217-8.
39. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf 1999;20:25-41.
40. Wilms EB, Touw DJ, Heijerman HG, et al. Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol 2013;47:658-65.
41. Yousef AA, Jaffe A. The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev 2010;11:108-14.
42. Willekens J, Eyns H, Malfroot A. How long should we maintain long-term azithromycin treatment in cystic fibrosis patients? Pediatr Pulmonol 2014, http://dx.doi.org/10.1002/ppul.22981.
43. Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther 2009;22:467-72.
44. Hansen CR, Pressler T, Hoiby N, et al. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros 2009;8:58-62.
45. Tramper-Stranders GA, Wolfs TF, Fleer A, et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007;26:8-12.
46. Touati A, Peuchant O, Jensen JS, et al. Direct detection of macrolide resistance in Mycoplasma genitalium isolates from clinical specimens from France by use of real-time PCR and melting curve analysis. J Clin Microbiol 2014;52: 1549-55.
47. Catherinot E, Roux AL, Vibet MA, et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 2013;41:1101-6.
48. Binder AM, Adjemian J, Olivier KN, et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013;188:807-12.
49. Bargon J, Dauletbaev N, Kohler B, et al. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999;93:835-8.
50. Jubin V, Ranque S, Stremler Le Bel N, et al. Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010;45:764-71.
51. Howard PA. Azithromycin-induced proarrhythmia and cardiovascular death. Ann Pharmacother 2013;47:1547-51.
52. Albert RK, Schuller JL. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med 2014;189:1173-80.
53. Mosholder AD, Nambiar S. Cardiovascular risks with azithromycin. N Engl J Med 2013;369:581.